PROF

Profound Medical Corp.'s stock price has been impacted by several events in the past six months. The company missed revenue expectations in Q4 2025, leading to a stock price decline. The CAPTAIN trial met its primary safety endpoint, showing superior outcomes for TULSA. TULSA-PRO achieved milestones, including Texas Prostate completing its 100th procedure and an installed base reaching 78 systems. In December 2025, the company announced expected funding and filed a follow-on equity offering. In May 2026, Profound Medical reported strong first-quarter 2026 financial results, with revenue up 104% year-over-year, and announced Humana coverage for the TULSA Procedure. Despite beating Q1 2026 earnings per share and revenue estimates, the stock experienced a slight decrease on May 8, 2026.